Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Posted inHematology-Oncology news Oncology

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma

Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 trials in relapsed/refractory multiple myeloma.
Seborrheic Dermatitis and Epithelial Barrier Diseases: Large Cohort Studies Support a Shared Barrier‑Driven Pathogenesis
Posted inAllergy & Immunology Dermatology news

Seborrheic Dermatitis and Epithelial Barrier Diseases: Large Cohort Studies Support a Shared Barrier‑Driven Pathogenesis

Two large US retrospective cohort studies show seborrheic dermatitis is strongly associated with a range of epithelial barrier diseases (skin, respiratory, gastrointestinal, ocular), with evidence of bidirectional risk. Findings support the epithelial barrier theory and prompt integrated clinical awareness and mechanistic research.
Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship
Posted inDermatology news

Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship

A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting antibiotic-associated dysbiosis may reduce biologic persistence.
Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Posted inClinical Updates news Oncology Urology

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Comprehensive review of metformin's role in metastatic prostate cancer with ADT highlights STAMPEDE trial's findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced effects on metabolic syndrome and progression outcomes.
Type 3c Diabetes from Chronic Pancreatitis: Mechanisms, Diagnosis, and Practical Management
Posted inDiabetes & Endocrinology Gastroenterology news

Type 3c Diabetes from Chronic Pancreatitis: Mechanisms, Diagnosis, and Practical Management

This article synthesizes current understanding of type 3c diabetes (T3cDM) caused by chronic pancreatitis—covering pathophysiology (islet loss, exocrine insufficiency, altered incretin and hepatic/peripheral insulin sensitivity), diagnostic approaches, and pragmatic treatment strategies including enzyme replacement and tailored glycemic therapy.
Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use
Posted innews Pediatrics Psychiatry

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipolar spectrum disorders taking second‑generation antipsychotics.
Stepped Care Plus Cash Incentives Cuts 3‑Year Diabetes Incidence in Multiethnic Asian Prediabetes Cohort
Posted inAI Diabetes & Endocrinology news

Stepped Care Plus Cash Incentives Cuts 3‑Year Diabetes Incidence in Multiethnic Asian Prediabetes Cohort

The Pre-DICTED randomized trial found a stepped-care diabetes prevention program augmented with financial incentives reduced 3‑year diabetes conversion (34.8% vs 47.3%; adjusted RR 0.74), with metformin added for persistent high-risk participants and modest increased adverse events largely from GI symptoms.
AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-driven analysis identifies muscle volume as a robust predictor of survival in NSCLC, highlights metformin-modulated adipose effects, and elucidates molecular links to the obesity paradox, informing personalized prognosis beyond BMI.
SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Posted inDiabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermediate baseline fibrosis.
Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
Posted innews Pediatrics Psychiatry

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with second-generation antipsychotics.